United Therapeutics (NASDAQ:UTHR) reported modestly weaker Q1 results—$781.5M revenue, down 1.6% YoY, and EPS missing estimates—sending the stock lower, while the company moved to bolster its pipeline by agreeing to acquire Thymmune for up to $300M to advance iPSC-derived thymic therapy THY-100.
Previous Week Recap
- United Therapeutics Q1 Revenue Dip: United Therapeutics Q1 2026 revenue $781.5M, down 1.6% YoY. EPS missed estimates by 1.9%. Stock fell about 4.8% to ~$544.70 after the report.
- United Therapeutics Buys Thymmune: United Therapeutics to buy Thymmune for $140M cash plus up to $160M in milestones (total $300M) for iPSC-derived thymic cell therapy platform and lead candidate THY-100 targeting congenital athymia.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.